When looking for a treatment for lung cancer, patients must consider all your choices, including information about the treatment protocol, risks, and potential outcomes. The Regeneration Center has helped many lung cancer patients by using personalized and safe cancer immunotherapies that are explicitly tailored based on the type and stage of lung cancer that you or a loved one may have, including Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC).

Our Functional medical oncology programs offer several treatment solutions using standard cancer treatment techniques such as:

• Chemotherapy
• Surgical Resection
• Radiation therapy
• Natural Killer Cell Therapy “NK Cells”
• HSC+ T lymphocytes Cells for Biphasic Mesothelioma
• Oncolytic virotherapy

Cellular Immunotherapy for Lungs

Alternative Treatment for Lung Carcinoma

We also offer the latest in Alternative Non-Invasive Lung cancer therapies, including:

• High-Intensity Focused Ultrasounds or HIFU
• Photodynamic Cancer Therapy
• Modified T-Cell Therapy
• Stem Cell and Dendritic Cell Therapy
• Cyberknife and Cryosurgery
• Electrocautery
• Internal Radiation Therapy

Modified T & Dendritic Cell Therapy

Complementary & Alternative Treatment for Lung Cancers

Our oncology team is based in Bangkok and offers the latest innovations for the treatment of lung cancer. Small Cell Lung cancer is the leading cause of death in Thailand and also in many other countries around the world and is plaguing millions of people each year. Our treatment measures have proven our ability to induce remission of the disease and halt any further spreading through our advanced lung cancer treatment procedures such as HIFU, Cyberknife, chemotherapy, radiotherapy, or minimally invasive surgery without the need for risky lung transplants.

T lymphocyte immunotherapy is not appropriate for all stages and can be used to treat subcutaneous and lung tumors using modified immune cell therapy. Our treatment protocol works by isolating and expanding immune cells to target the metabolic disease and slow down further cell proliferation. This action subsequently inhibits the rapid rate of tumor growth [1]. The underlying model of action for the treatment can be attributed mainly to the results of angiogenesis (creation of new blood cells/vessels).

Treatments for Small Cell Lung Cancer (SCLC)

Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by rapid growth and early metastasis. The primary treatment options for SCLC typically include chemotherapy, radiation therapy, and, in some cases, surgery. However, patients may consider alternative or complementary treatments alongside conventional treatments. These alternatives often focus on managing symptoms, improving quality of life, and potentially enhancing the effectiveness of standard therapies, especially those with a diagnosis due to genotoxic exposure.

• Targeted Therapy – While more commonly associated with non-small cell lung cancer, some forms of targeted therapy are being explored for SCLC. Targeted therapies attack specific molecules involved in cancer cell growth and survival. Research into targeted therapies for SCLC is ongoing, focusing on specific genetic mutations or protein expressions that may be present in specific disease subtypes.
• Immunotherapy – Immunotherapy is a promising treatment that helps the body’s immune system recognize and attack cancer cells more effectively. Medications like checkpoint inhibitors (e.g., atezolizumab, durvalumab) are now being used in combination with chemotherapy for certain types of SCLC, particularly extensive-stage disease. These drugs block proteins that prevent the immune system from attacking cancer cells, potentially leading to better outcomes.

CAR-T cell therapy for Lung Cancer

Current gene therapies plus regenerative therapies are combined with HSC+ cells and used to treat respiratory conditions such as lung disease,  COPD, emphysema, liver disease, Idiopathic Pulmonary Fibrosis, and pancreatitis. Mesenchymal and dendritic cells can be used in conjunction with traditional radiotherapy, and chemotherapy treatments have proven to help promote the rapid restoration of the patient’s peripheral blood parameters after irradiation and chemotherapy alternatives for patients with kidney cancer. ^[2]

Recovery does take time, but patients have been shown to make significant physical improvements in overall body function, and using cells from the patient also helps to prevent the severe complications and side effects associated with irradiation with an improved quality of life.^[3]

Cancer research programs at Chulaborn Hospital and Queen Sirikit Cancer Center have been recognized worldwide as we aim to maximize lung function despite the disease’s aggressive nature.[4] With that, our deeper purpose is to slowly reach that point wherein certain death is not imminent as it used to be in the past for cancer patients. We believe that through our research and technology initiatives, advanced treatments for stage 4 pancreatic cancer, colon cancer, and late-stage prostate cancer have become a reality ^[5]

T-cell replacement

T-cell-based therapies, particularly those involving genetically modified T-cells, are an exciting new development in cancer treatment, including for lung cancer. The primary approach involves CAR T-cell therapy and T-cell receptor (TCR) therapy, both of which are forms of immunotherapy designed to harness and enhance the body’s immune system to target and kill cancer cells.

CAR T-Cell Therapy

Chimeric Antigen Receptor (CAR) T-cell therapy is a type of immunotherapy where a patient’s T-cells are genetically engineered to better recognize and attack cancer cells. Here’s how it generally works at the Regeneration Center:

• Extraction: T-cells are collected from the patient’s blood, usually on day 2 of treatment
• Genetic Engineering & Modifications: These T-cells are genetically modified in our lab in Bangkok to express a chimeric antigen receptor (CAR) on their surface. This receptor is specifically designed to recognize and bind to a particular protein found on the surface of cancer cells.
• Expansion: The modified T-cells are expanded over 2-3 weeks to produce millions of CAR T-cells needed for treatment
• Infusion: The modified T-cells are infused back into the patient, seeking out and destroying cancer cells that express the target antigen.

While CAR T-cell therapy has shown remarkable success in treating some types of blood cancers (like leukemia and lymphoma), its application to solid tumors such as lung cancer, including both small cell and non-small cell lung cancer, is more complex. Challenges of CAR T-cell therapy include:

• Tumor Microenvironment: The complex and immunosuppressive microenvironment of solid tumors can inhibit the effectiveness of CAR T-cells.
• Target Identification: Identifying a suitable target antigen unique to cancer cells and not found in healthy cells is more difficult in solid tumors, increasing the risk of off-target effects and toxicity.
• T-cell Trafficking and Infiltration: Efficiently directing CAR T-cells to the tumor site and enabling them to infiltrate solid tumors remains a significant hurdle.

T-Cell Receptor (TCR) Therapy

TCR therapy is another form of T-cell therapy that differs from CAR T-cell therapy in how it recognizes cancer cells. Unlike CAR T-cells that recognize surface antigens, TCR-engineered T-cells recognize antigens presented by the major histocompatibility complex (MHC) on the surface of cancer cells. This target specificity in TCR therapies allows us to target a broader range of antigens, including intracellular proteins, which are not accessible to CAR T-cells.

Similar to CAR T-cell therapy, TCR therapy involves extracting a patient’s T-cells, genetically modifying them to express a specific TCR targeting a tumor-associated antigen, expanding these modified T-cells, and infusing them back into the patient. TCR therapy is potentially more versatile than CAR T-cell therapy for solid tumors like lung cancer because it can target a broader range of antigens. However, it also faces challenges related to the tumor microenvironment and the need for precise matching between the TCR and the patient’s MHC type.

Stem Cell Treatment for Lung Cancer in 2025

Our goal is to guide you every step of the way. Our medical team will examine your needs thoroughly to determine the ideal protocol. Regeneration center cancer protocols are based on proven clinical trial results and offer a comprehensive cancer treatment program specifically targeting specific lymph nodes and malignancies with the least side effects. Cancer treatments in Thailand are customized to the needs of the patient without chemotherapy drugs or radiation therapies. Our doctors must consider other factors, such as the patient’s underlying medical conditions and history.

We aim to provide advanced and customized treatment using our doctors’ intense training, international expertise, and state-of-the-art medical facilities. Together, we will work toward that stage of remission, where you may be safely declared cancer-free without any further chances for remission. It is of utmost importance to us that we provide you with a sensible treatment plan that can help eradicate the disease without any complications or compromise lung function or any adjacent internal organs.

 Lung Cancer Stage I-IV Treatment Guidelines – 2025

Our cancer stem cell treatment and research center continues to probe further than ever before. With discoveries in cell communications, clinical trials, and methods of diagnosing and treating lung cancer, we firmly believe that we are well on our way to managing an otherwise fatal to allow our patients to finally live a cancer-free life without the constant fear of relapse.

To determine eligibility and get exact prices along with a day-by-day treatment outline, our oncologists will need to better understand the patient’s existing needs via recent histological results, Biopsies, genetic tests, blood tests, x-rays, scans, bone marrow sample results, or clinical diagnosis from your oncologist.

If you or a loved one has been diagnosed with cancer, be aware of alternative medical solutions to fight cancer using HSC+ immune cells. Take the first step toward treatment by allowing your care to be handled by our team of experts in our advanced facility. We are here to help. To learn more about our safe and effective treatment options for lung cancer, please contact us today.

Published Clinical Citations

[1] ^ Mulvihill, Michael S, Johannes R Kratz, Patrick Pham, David M Jablons, and Biao He. 2012. The role of stem cells in airway repair: implications for the origins of lung cancer. Chinese journal of cancer, no. 2 (November 1). doi:10.5732/cjc.012.10097. https://www.ncbi.nlm.nih.gov/pubmed/23114089

[2] ^ Phunmanee, Anakapong, Kosin Wirasorn, Yupa Thavornpitak, Aumkhae Sookprasert, and Jarin Chindaprasirt. 2012. Lung cancer in hospitalized patients of Thailand. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. https://www.ncbi.nlm.nih.gov/pubmed/23130455

[3] ^ Singh, Sandeep, Jose Trevino, Namrata Bora-Singhal, Domenico Coppola, Eric Haura, Soner Altiok, and Srikumar P Chellappan. 2012. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Molecular cancer (September 25). doi:10.1186/1476-4598-11-73. https://www.ncbi.nlm.nih.gov/pubmed/23009336

[4] ^ Swangsilpa, Thiti, Pornpan Yongvithisatid, Kumutinee Pairat, Patchareporn Dechsupa, Mantana Dhanachai, Somjai Dangprasert, Ladawan Narkwong, et al. 2012. Preliminary experience of CyberKnife treatment of primary non-small cell lung cancer. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, no. 10. https://www.ncbi.nlm.nih.gov/pubmed/23193750

[5] ^ Wang, Ping, Quanli Gao, Zhenhe Suo, Else Munthe, Steinar Solberg, Liwei Ma, Mengyu Wang, Nomdo Anton Christiaan Westerdaal, Gunnar Kvalheim, and Gustav Gaudernack. 2013. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PloS one, no. 3 (March 4). doi:10.1371/journal.pone.0057020. https://www.ncbi.nlm.nih.gov/pubmed/23469181